This page shows the latest Alcon news and features for those working in and with pharma, biotech and healthcare.
eye care division Alcon earlier this year.
The Switzerland-headquartered firm has just spun off its eye care division Alcon, raising $4.7bn in the process, and helping it to create a leaner firm focused on medicines, and ... Novartis is off to a strong start in 2019 with the Mayzent launch,
Novartis already have the spin-off of its eyecare division Alcon in the pipeline, with the business unit to be divested in the first half of this year.
The company also announced cuts to its manufacturing operations, and confirmed the spin off of eyecare division Alcon, which could raise as much as $35bn this year.
from its eye-division Alcon, which it acquired back in 2010.
The decision is in contrast to firms such as Novartis (selling its eyecare divison Alcon) and Lilly, which just announced the spin-off its animal health division Elanco.
More from news
Approximately 17 fully matching, plus 52 partially matching documents found.
To date it seems Sanofi is also considering a move. Meanwhile Novartis is reportedly considering a sale of its contact lens business which is part of the Alcon eye care division.
Remaining revenues will come from pharmaceuticals, eye care (Alcon) and generics (Sandoz) and of course its stake in GSK Consumer Health.
Developed by Alcon (a Novartis company) this comprehensive tool is designed to teach doctors how to make diagnoses using an ophthalmoscope.
Our new eye-care business Alcon is also driving our growth, with net sales increasing six per cent in Q2.". ... Alcon is already delivering solid sales growth, with sales up six per cent on a proforma basis in the second quarter.
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Prior to her tenure at Celgene, Fouse worked for Alcon Laboratories, an ophthalmic pharmaceutical and medical device company.
Previously, Dr Fouse was chief financial officer of agribusiness and food company Bunge, and also brought executive leadership expertise from Alcon Laboratories and Nestlé.
Meanwhile, at he served at GSK as VP of clinical ophthalmology, helping build its early stage clinical pipeline, and was VP and head of pharmaceutical product development at Novartis/Alcon.
Ball has been appointed as the new division head and chief executive officer of Alcon, replacing Jeff George, and is set to focus on its surgical and vision care division. ... Joseph Jimenez, chief executive officer of Novartis, said: “His expertise in
Prior to his appointment as a board member of Novaliq, Dr Cagle was senior vice president of Alcon R&D and chief scientific officer from 1996 to mid-2008 having worked ... as a member of Alcon's research and development team for over thirty years.
More from appointments
Approximately 1 fully matching, plus 10 partially matching documents found.
Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...